Jeff Baker

“Results in both plasma and patient affordability show the momentum we have been building. We also drove year-over-year margin improvement across the entire income statement, even excluding a one-time non-cash benefit of $990,000 related to the carrying value of the gamma acquisition earn-out liability.”

“As Mark highlighted, our first quarter results reflect the continued momentum in our business, the growing financial impact of our patient affordability platform, and the inflection point we have reached as it relates to operating leverage.”

“As Mark said, we had a solid first quarter driven by the momentum we are experiencing with our patient affordability business. Our results for the quarter exceeded our expectations despite weakness in our plasma business related to excess industry-wide inventory levels as we discussed on our last conference call.”

“As Mark said, we executed on another good quarter. Plasma donor compensation revenue increased $378,000 versus the same period last year or 3.4% to $11.44 million.”

“Keep in mind, Gary, some of those are direct. Some of those are through hubs, which represent a number of different pharmaceutical companies. So it's hard - I mean we have the number, but let's say that it's XYZ Pharma Company, if they're coming through a hub with another XYZ Pharma Company has no relationship.”